Clinical Trial

Validating Gulf War Illness Blood Biomarkers

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators goals are to identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI. To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-09; most recent amendment 2025-07-21.
Trial Details
NCT Number NCT05736146
Lead Sponsor Roskamp Institute Inc.
Collaborators: Boston University, Palo Alto Veterans Institute for Research, United States Department of Defense
Conditions Gulf War Syndrome, Gulf War Illness
Enrollment 100 participants
Start Date 2022-06-30
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-24